Gecacitinib (JAK inhibitor)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-03 — A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV: Early-phase clinical trial evaluating Gecacitinib hydrochloride combined with pegylated interferon in PV, with hematological remission at 24 weeks as the primary endpoint — first-in-class pairing of this novel JAK inhibitor with pegIFN. (novelty: 4)
Open questions
Related
Contributing findings
A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV
03-mar-2026
novelty 4
per-area 4
introduces